Sign In
Buy AEZS
$5.72
+0 (+0%)
At Close: Nov 13, 2024
Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million
10:00pm, Tuesday, 16'th Feb 2021
CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and dev
Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares
05:19pm, Tuesday, 16'th Feb 2021
CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and dev
AEZS Stock Price Increased 237.37% Over The Past Week: Why It Happened
07:26am, Tuesday, 09'th Feb 2021
The stock price of AEterna Zentaris Inc. (NASDAQ: AEZS) went up 237.37% over the past week. This is why it happened.
AEZS Stock Price Increases Over 50% Pre-Market: Why It Happened
07:52am, Tuesday, 02'nd Feb 2021
The stock price of AEterna Zentaris Inc. (NASDAQ: AEZS) is trading at over 50% pre-market as of 7:48 AM. This is why it happened.
- Company secures next step to continue to build-out pipeline of assets
Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics
08:05am, Thursday, 28'th Jan 2021
- Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of neuromyelitis op
Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
04:05pm, Tuesday, 26'th Jan 2021
CHARLESTON, S.C., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeut
Aeterna Zentaris to Present at NobleCon17
08:05am, Friday, 15'th Jan 2021
– Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, January 20th at 12:00 PM ET –
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
08:05am, Tuesday, 05'th Jan 2021
CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeut
Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin
08:05am, Monday, 07'th Dec 2020
CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary, (“Aeterna” or the “Company”), a specialty biopharmace
Aeterna Zentaris Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin
08:05am, Monday, 16'th Nov 2020
- Company to receive upfront payment of €5 million replacing a later stage regulatory approval milestone of U.S.$5 million - Novo Nordisk committing to fund €9 million of the budgeted AEZS-130-
Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update
08:35am, Friday, 06'th Nov 2020
– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021
Wall Street Breakfast: The Week Ahead
04:42am, Sunday, 06'th Sep 2020
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
08:21am, Saturday, 05'th Sep 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Aeterna Zentaris Reports Second Quarter 2020 Financial Results and Provides Business Update
12:35pm, Thursday, 06'th Aug 2020
– Positive results from AEZS-130-P01 (“Study P01”) confirmed dosing regimen of macimorelin as a potential diagnostic for childhood-onset growth hormone deficiency– Safety and efficacy study AE
